



Approved for use through 10/31/2002. OMB 0951-0031  
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |                          |                          |                        |              |
|---|---|--------------------------|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO   |   | <b>Complete If Known</b> |                          |                        |              |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   | Application Number       | 10/052,092               |                        |              |
|   |   | Filing Date              | January 18, 2002         |                        |              |
|   |   | First Named Inventor     | Suzanne Fuqua            |                        |              |
|   |   | Art Unit                 | N/A- 1634                |                        |              |
|   |   | Examiner Name            | Not Yet Assigned Switzer |                        |              |
| Sheet   | 1 | of                       | 4                        | Attorney Docket Number | HO-P02102US2 |

TECH CENTER 1600/2500

NOV 01 2002

RECEIVED

| U.S. PATENT DOCUMENTS |             |  |                                |  |  |
|-----------------------|-------------|--|--------------------------------|--|--|
| Examiner<br>Initials* | Cite<br>No. | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant<br>of Cited Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |
|                       |             | Number-Kind Code <sup>2</sup> (if known) |                                |  |  |
| AB                    | AA          | 5563035-                                 | 10-08-1996                     | Weigel   |  |
|                       | AB          | 6162606-                                 | 12-19-2000                     | Raam   |  |

| FOREIGN PATENT DOCUMENTS |             |   |                                |  |  |
|--------------------------|-------------|---|--------------------------------|--|--|
| Examiner<br>Initials*    | Cite<br>No. | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant<br>Passages or Relevant<br>Figures Appear |
|                          |             | Country Code <sup>2</sup> -Number <sup>2</sup> -Kind Code <sup>2</sup> (if known) |                                |  |  |
|                          |             |   |                                |  |  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 601.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbol(s) as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

|                |                |                    |         |
|----------------|----------------|--------------------|---------|
| 25224662<br>.1 | <i>Switzer</i> | Date<br>Considered | 6/24/03 |
|----------------|----------------|--------------------|---------|



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0851-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

## Complete If Known

Application Number 10/052,092  
 Filing Date January 18, 2002  
 First Named Inventor Suzanne Fuqua  
 Art Unit N/A  
 Examiner Name Not Yet Assigned  
 Attorney Docket Number HO-P02102US2

TECH CENTER 1600/2900

NOV 01 2002

RECEIVED

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cls No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published. | 1* |
|-------------------|---------|--|----|
| 92                | CA      | Burstein, Nelson A.; Overall Principles of Cancer Management - Hormone Therapy; published in Cancer, A Manual for Practitioners (American Cancer Society Massachusetts Division); 6th Edition, 1992, pages 67 - 71   |    |
|                   | CB      | Donner, William L.; Prognostic Factors; Cancer 1992; 70:1755 - 1764  |    |
|                   | CC      | Brooks, S. C., et al.; Relation of Tumor Content of Estrogen and Progesterone Receptors with Response of Patient to Endocrine Therapy; Cancer 48:2775 - 2778, 1980   |    |
|                   | CD      | Degenshein, George A., et al.; The Value of Progesterone Receptor Assays in the Management of Advanced Breast Cancer; Cancer 48:2789 - 2793, 1980  |    |
|                   | CE      | Fuqua, Suzanne A. W., et al.; Variant Human Breast Tumor Estrogen Receptor with Constitutive Transcriptional Activity; Cancer Research 51:105 - 109, January 1, 1991   |    |
|                   | CF      | Gelbfish, Gary A., et al.; Relationship of Estrogen and Progesterone Receptors to Prognosis in Breast Cancer; Ann Surg. 207(1):75 - 79, January 1993   |    |
|                   | CG      | Greene, Geoffrey, et al.; Sequence and Expression of Human Estrogen Receptor Complementary DNA; Science Vol. 231, pages 1150 - 1154; March 7, 1986   |    |
|                   | CH      | Kohail, Hanana M., et al.; A Multifactorial Analysis of Steroid Hormone Receptors in Stages I and II Breast Cancer; Ann. Surg 201(5):611 - 617, May, 1985  |    |
|                   | CI      | Elledge, Richard M., et al.; Prognostic Factors and Therapeutic Decisions in Axillary Node-Negative Breast Cancer; Annu. Rev. Med. 1993, 44:201 - 210  |    |
|                   | CJ      | McGuire, William L.; Prognostic factors for recurrence and survival in human breast cancer; Breast Cancer Research and Treatment 10:5 - 9, 1987  |    |
|                   | CK      | Mills, Rosemary R.; Correlation of Hormone Receptors with Pathological Features in Human Breast Cancer; Cancer 48:2869 - 2871, 1980  |    |
|                   | CL      | McCarty, Kenneths, et al.; Correlation of Estrogen and Progesterone Receptors with Histologic Differentiation in Mammary Carcinoma; Cancer 48:2851 - 2858, 1980  |    |
|                   | CM      | O'Connell, Peter, et al.; Loss of Heterozygosity at D14S62 and Metastatic Potential of Breast Cancer; REPORTS, Journal of the National Cancer Institute, Vol. 91(16), pages 1391 - 1397; August 18, 1999   |    |
|                   | CN      | Shousha, S., et al.; Oestrogen receptors in mucinous carcinoma of the breast: an immunohistological study using paraffin wax sections; J. Clin. Pathol. 1989; 42:902 - 905   |    |
|                   | CO      | Shousha, S., et al.; Immunohistological study of oestrogen receptors in breast carcinomas that are biochemically receptor negative; J. Clin. Pathol. 1990; 43:239 - 242  |    |
|                   | CP      | Williams, M. R., et al.; Oestrogen receptors in primary and advanced breast cancer: An eight year review of 704 cases; Br. J. Cancer (1987), 55:67 - 73  |    |
|                   | CQ      | Vogelstein, Bert, et al.; The multistep nature of cancer; TiG Vol. 9 (4), pages 138 - 141, April 1993  |    |
|                   | CR      | Weigel, Ronald J., et al.; Transcriptional Control of Estrogen Receptor In Estrogen Receptor-negative Breast Carcinoma; Cancer Research, Vol. 53 (15):3472 - 3474, August 1, 1993  |    |
|                   | CS      | Scott, Gary K., et al.; Truncated Forms of DNA-binding Estrogen Receptors in Human Breast Cancer; J. Clin. Invest. 1991, 88:700 - 706  |    |
|                   | CT      | Ince, B. Avery, et al.; Powerful Dominant Negative Mutants of the Human Estrogen Receptor; The Journal of Biological Chemistry, Vol. 268 (19), 14028 - 14032, 1993   |    |
|                   | CU      | Fuqua, Suzann A. W., et al.; Inhibition of Estrogen Receptor Action by a Naturally Occurring Variant In Human Breast Tumors; Cancer Research 52:483 - 486, January 15, 1992  |    |
| 92                | CV      | Castles, Carl G., et al.; Expression of a Constitutiv ly Active Estrogen Receptor Variant in the Estrogen Receptor-negative BT-20 Human Breast Cancer Cell Line; Cancer Res arch 53  |    |

→ completed next page

25224662  
1

Date Considered

6/24/03



Under the Patent Information Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)  
Approved for use through 10/31/2002 OMB 0951-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

## Complete If Known

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/052,092       |
| Filing Date            | January 18, 2002 |
| First Named Inventor   | Suzanne Fuqua    |
| Art Unit               | N/A              |
| Examiner Name          | Not Yet Assigned |
| Attorney Docket Number | HO-P02102US2     |

|    |     |   |  |
|----|-----|---|--|
|    |     | (24):5934 - 5939, December 15, 1993   |  |
| 95 | CW  | Keaveney, M., et al.; Evidence for a Previously Unidentified Upstream Exon in the Human Oestrogen Receptor Gene; J. Mol. Endocr., Vol. 6:111 - 115, 1991  |  |
|    | CX  | Piva, R., et al.; Sequencing of an RNA Transcript of the Human Estrogen Receptor Gene: Evidence for a New Transcriptional Event; J. Steroid Biochem. Molec. Biol., Vol. 46 (5), pages 531 - 538, 1993   |  |
|    | CY  | McDonnell, Donald P.; The Molecular Pharmacology of SERMs; TEM, Vol. 10 (8):301 - 311, 1999   |  |
|    | CZ  | Barkhem, Tomas, et al.; Differential Response of Estrogen Receptor a and Estrogen Receptor B to Partial Estrogen Agonists/Antagonists; Molecular Pharmacology, 54:105 - 112, 1998   |  |
|    | CA1 | Sun, Jun, et al.; Novel Ligands that Function as Selective Estrogens or Antiestrogens for Estrogen Receptor-a or Estrogen Receptor-B; Endocrinology, Vol. 140 (2):800 - 804, 1999   |  |
|    | CB1 | McDonnell, Donald P., et al.; Cellular Mechanisms Which Distinguish between Hormone- and Antihormone-Activated Estrogen Receptor; Annals New York Academy of Sciences, 761:121 - 137  |  |
|    | CC1 | Barkhem, Tomas, et al.; Characterization of the "Estrogenicity" of Tamoxifen and Raloxifene in HepG2 Cells: Regulation of Gene Expression from an ERE Controlled Reporter Vector Versus Regulation of the Endogenous SHBG and PS2 Genes; J. Steroid Biochem. Molec. Biol., Vol. 62 (1), pages 53 - 64, 1997 |  |
|    | CD1 | Cowley, Shaun M., et al.; Estrogen Receptors a and B Form Heterodimers on DNA; The Journal of Biological Chemistry, Vol. 272 (32), pages 19858 - 19862, August 8, 1997  |  |
|    | CE1 | Paige, Lisa A., et al.; Estrogen receptor (ER) modulators each induce distinct conformational changes in ER a and ER B; Proc. Natl. Acad. Sci. USA, Vol. 96, pages 3999 - 4004, March 1999  |  |
|    | CF1 | Shiau, Andrew K., et al.; The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen; Cell, Vol. 95, pages 927 - 937, December 28, 1998  |  |
|    | CG1 | Cowley, Shaun M., et al.; A comparison of transcriptional activation by ERa and ERB; Journal of Steroid Biochemistry and Molecular Biology, Vol. 69, pages 165 - 175, 1999  |  |
|    | CH1 | Tremblay, Gilles B., et al.; Cloning, Chromosomal Localization, and Functional Analysis of the Murine Estrogen Receptor B; Molecular Endocrinology 11:353 - 365, 1997   |  |
|    | CI1 | Wilkowska, H. Ewa, et al.; Characterization of bacterially expressed rat estrogen receptor B ligand binding domain by mass spectrometry: Structural comparison with estrogen receptor a; Steroids 62:621 - 631, 1997  |  |
|    | CJ1 | McGuire, William L., et al.; Estrogen Receptor Variants in Clinical Breast Cancer; Molecular Endocrinology 5:1571 - 1577, 1991  |  |
|    | CK1 | van Agthoven, Ton, et al.; Differential Expression of Estrogen, Progesterone, and Epidermal Growth Factor Receptors in Normal, Benign, and Malignant Human Breast Tissues using Dual Staining Immunohistochemistry; American Journal of Pathology, Vol. 144 (6), pages 1238 - 1246, June 1994               |  |
|    | CL1 | Zhang, Zhi-Xia, et al.; An Estrogen Receptor Mutant with Strong Hormone-independent Activity from a Metastatic Breast Cancer; Cancer Research 57:1244 - 1249, April 1, 1997   |  |
|    | CM1 | Tremblay, Gilles B., et al.; Ligand-independent Activation of the Estrogen Receptors a and B by Mutations of a Conserved Tyrosine Can Be Abolished by Antiestrogens; Cancer Research 58:877 - 881, March 1, 1998  |  |
|    | CN1 | Anandappa, Shanay Y., et al.; Variant estrogen Receptor a mRNAs in Human Breast Cancer Specimens; Int. J. Cancer; 88, pages 209 - 216, 2000   |  |
| 96 | CO1 | Schuur, Eric R., et al.; Monoallelic Amplification of Estrogen Receptor-a Expression in Breast Cancer; Cancer Research 60, pages 2598 - 2601, May 15, 2000  |  |

25224962

Date Considered

6/25/03



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/R&A (10-01)

Approved for use through 10/31/2002. OMB 0951-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

### Complete If Known

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/052,092       |
| Filing Date            | January 18, 2002 |
| First Named Inventor   | Suzanne Fuqua    |
| Art Unit               | N/A              |
| Examiner Name          | Not Yet Assigned |
| Attorney Docket Number | HO-P02102US2     |

Sheet 4 of 4

|     |   |  |
|-----|---|--|
| CP1 | Fasco, Michael J., et al.; Expression of an estrogen receptor alpha variant protein in cell lines and tumors; <i>Molecular and Cellular Endocrinology</i> 162, pages 167 - 180, 2000                            |  |
| CQ1 | Rost, Natalia S., et al.; Immunochemical analyses of estrogen receptors in human breast tumors by a novel monoclonal estrogen receptor antibody (EVG F9); <i>Steroids</i> 65, pages 429 - 436, 2000             |  |
| CR1 | O'Connell, Peter, et al.; Analysis of Loss of Heterozygosity in 399 Premalignant Breast Lesions at 15 Genetic Loci; <i>Journal of the National Cancer Institute</i> , Vol. 90 (9), pages 697 - 703; May 8, 1998 |  |
| CS1 | Page, David L., et al.; Premalignant and Malignant Disease of the Breast: The Roles of the Pathologist; <i>Mod Pathol</i> 1998; 11(2):120 - 128   |  |
| CT1 | Page, David L.; The Woman at High Risk for Breast Cancer - Importance of Hyperplasia; <i>Special Problems in Breast Cancer Therapy</i> , Vol. 76 (2), pages 221 - 230, April 1996                               |  |
| CU1 | Roger, Pascal, et al.; Dissociated Overexpression of Cathepsin D and Estrogen Receptor Alpha in Preinvasive Mammary Tumors; <i>Human Pathology</i> , Vol. 31 (5), pages 593 - 600, May 2000                     |  |
| CV1 | Lishman, S. C., et al.; Atypical lobular hyperplasia and lobular carcinoma in situ: surgical and molecular pathology; <i>Histopathology</i> 1999, 35, 195 - 200   |  |
| CW1 | Page, David L., et al.; Evaluation and Management of High Risk and Premalignant Lesions of the Breast; <i>World J. Surg.</i> 18, 32 - 38, 1994  |  |
| CX1 | Page, David L., et al.; Anatomic Markers of Human Premalignancy and Risk of Breast Cancer; <i>Cancer</i> 66:1326 - 1335, 1990   |  |
| CY1 | Cardiff, R. D., et al.; Biology of Breast Preneoplasia; <i>Cancer</i> 39:2734 - 2746, 1977  |  |
| CZ1 | Stoll, B. A.; Premalignant Breast Lesions: Role for Biological Markers in Predicting Progression to Cancer; <i>European Journal of Cancer</i> , Vol. 35 (9), pages 693 - 697, 1999                              |  |
| CA2 | Sientz-Kessler, Kimberly, et al.; Identification of the Human Mnk2 Gene (MKNK2) through Protein Interaction with Estrogen Receptor B; <i>Genomics</i> 69, 63 - 71, 2000   |  |
| CB2 | Dupont, William D., et al.; Risk Factors for Breast Cancer in Women with Proliferative Breast Disease; <i>N. Engl. J. Med.</i> 1985; 312:146 - 151  |  |
| CC2 | Lakhani, Sunil R.; The Transition from Hyperplasia to Invasive Carcinoma of the Breast; <i>Journal of Pathology</i> , 187:272 - 278, 1998   |  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.

|          |                    |                 |         |
|----------|--------------------|-----------------|---------|
| 25224662 | <i>[Signature]</i> | Date Considered | 6/24/03 |
|----------|--------------------|-----------------|---------|